Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
[fr] Les cellules CAR-T représentent une nouvelle approche d'immunothérapie antitumorale dont
l'efficacité dans les hémopathies malignes B a récemment conduit à leur autorisation de mise
sur le marché. Les résultats des essais cliniques réalisés dans ce contexte ont montré que certaines
caractéristiques immunologiques des patients avant (au moment de l'aphérèse) et après admi-
nistration du traitement, ou des cellules CAR-T elles-mêmes, sont corrélées à la réponse au
traitement ou à sa toxicité. Il n'existe cependant pas à ce jour de recommandations sur le suivi
immunologique des patients traités en vie réelle. Les objectifs de cet atelier étaient de déterminer,
sur la base des données de la littérature et de l'expérience des centres, les examens immuno-
logiques à réaliser dans le cadre de la prise en charge d'un patient traité par cellules CAR-T. Ces
recommandations portent sur la caractérisation des cellules immunes du patient au moment de
l'aphérèse, la caractérisation des cellules CAR-T injectées, ainsi que le suivi des cellules CAR-T et des
autres paramètres de reconstitution immunitaire chez le patient après administration du traite-
ment. Une harmonisation des pratiques permettra de réaliser des études de corrélations clinico-
biologiques chez les patients traités en vie réelle dans le but de déterminer des facteurs prédictifs
de la réponse et de la toxicité. Ces données pourraient avoir un impact médico-économique
majeur en permettant d'identifier les patients qui vont bénéficier de manière optimale de ces
traitements coûteux. [en] CAR-T cells represent a new anti-tumor immunotherapy which has shown its clinical efficacy in B-
cell malignancies. The results of clinical trials carried out in this context have shown that certain
immunological characteristics of patients before (at the time of apheresis) and after the
administration of the treatment, or of the CAR-T cells themselves, are correlated with the
response to the treatment or to its toxicity. However, to date, there are no recommendations
on the immunological monitoring of patients treated in real life. The objectives of this workshop
were to determine, based on data from the literature and the experience of the centers, the
immunological analyses to be carried out in patients treated with CAR-T cells. The recommen-
dations relate to the characterization of the patient's immune cells at the time of apheresis, the
characterization of the injected CAR-T cells, as well as the monitoring of the CAR-T cells and other
parameters of immune reconstitution in the patient after administration of the treatment.
Harmonization of practices will allow clinical-biological correlation studies to be carried out in
patients treated in real life with the aim of identifying factors predictive of response and toxicity.
Such data could have a major medico-economic impact by making it possible to identify the
patients who will optimally benefit from these expensive treatments
Disciplines :
Hematology
Author, co-author :
Rubio, Marie; UMR 7563 IMoPa, CHRU Nancy, Hopital Brabois, Biopole de l'Université de Lorraine, CNRS, Vandoeuvre-les-Nancy, France
Varlet, Pauline; Laboratoire d'Immunologie, Université de Lille, CHU de Lille, LIRIC, Lille, France
Allain, Vincent; Laboratoire d'Immunologie, Université de Paris, Hôpital Saint-Louis, Nord, France
Ballot, Caroline; Établissement Français du Sang Hauts-de-France, Unité de Thérapie Cellulaire EFS site de Lille, Normandie, France
Cuffel, Alexis; Laboratoire d'Immunologie, Université de Paris, Hôpital Saint-Louis, Nord, France
Deschamps, Marina; UMR1098, Ets Bourgogne Franche-Comté, INSERM, Besançon, France
Ferrand, Christophe; UMR1098, Ets Bourgogne Franche-Comté, INSERM, Besançon, France
FOGUENNE, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie biologique et immuno-hématologie ; Unilab Lg, Liège, Belgique
Forcade, Edouard; CHU Bordeaux, service d'hématologie clinique et thérapie cellulaire, Bordeaux, France
Huynh, Anne; IUCT Oncopole, Toulouse, France
Guihot, Amélie; Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
Latouche, Jean-Baptiste; Laboratoire d'Immunologie et Biothérapies, CHU de Rouen, UMR Université/Inserm U1234, France
Lemarie, Claude; Institut Paoli-Calmettes, and Inserm CBT 1409, Centre d'Investigations Cliniques en Biothérapie, Marseille, France
Martinroche, Guillaume; Laboratoire d'Immunologie et Immunogénétique, place Amélie Raba Léon, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Morin, Florence; Laboratoire d'Immunologie, Université de Paris, Hôpital Saint-Louis, Nord, France
Nguyen, Stéphanie; Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
SCHMIT, Kathleen ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie biologique et immuno-hématologie ; Unilab Lg, Liège, Belgique
SERVAIS, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Simonetta, Federico; Division of Hematology, Department of Oncology, Faculty of Medicine and Translational Research Center for Oncohematology, Department of Internal Medicine Specialties, University of Geneva, Geneva University Hospitals, Geneva, Suisse
Yakoub-Agha, Ibrahim; INSERM U1286, Infinite, CHU de Lille, Univ Lille, Lille, France
Zucman, Sophie; Laboratoire d'Immunologie, Université de Paris, Hôpital Saint-Louis, Nord, France
Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Alternative titles :
[en] Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
June, C.H., Sadelain, M., Chimeric Antigen Receptor Therapy. N Engl J Med 379:1 (2018), 64–73.
Majzner, R.G., Mackall, C.L., Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 25:9 (2019), 1341–1355.
Du, M., Hari, P., Hu, Y., Mei, H., Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res, 8, 2020, 13.
Hayden, P.J., Sirait, T., Koster, L., Snowden, J.A., Yakoub-Agha, I., An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on beh**alf of the chronic malignancies working party of EBMT. Curr Res Transl Med, 2019.
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med 378:5 (2018), 439–448.
Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380:1 (2019), 45–56.
Locke, F.L., Ghobadi, A., Jacobson, C.A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20:1 (2019), 31–42.
Danylesko, I., Chowers, G., Shouval, R., Besser, M.J., Jacoby, E., Shimoni, A., et al. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med 68:1 (2019), 17–22.
Vercellino, L., Di Blasi, R., Kanoun, S., Tessoulin, B., Rossi, C., D'Aveni-Piney, M., et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 4:22 (2020), 5607–5615.
Dean, E.A., Mhaskar, R.S., Lu, H., Mousa, M.S., Krivenko, G.S., Lazaryan, A., et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4:14 (2020), 3268–3276.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., et al. Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies. Front Oncol, 9, 2019, 1237.
Schuster, S.J., Svoboda, J., Chong, E.A., Nasta, S.D., Mato, A.R., Anak, O., et al. Chimeric antigen receptor T-Cells in refractory B-Cell lymphomas. N Engl J Med 377:26 (2017), 2545–2554.
Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:5 (2018), 563–571.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380:18 (2019), 1726–1737.
Das, R.K., Vernau, L., Grupp, S.A., Barrett, D.M., Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov 9:4 (2019), 492–499.
Cohen, A.D., Garfall, A.L., Stadtmauer, E.A., Melenhorst, J.J., Lacey, S.F., Lancaster, E., et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129:6 (2019), 2210–2221.
Finney, O.C., Brakke, H.M., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest 129:5 (2019), 2123–2132.
Fraietta, J.A., Beckwith, K.A., Patel, P.R., Ruella, M., Zheng, Z., Barrett, D.M., et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127:9 (2016), 1117–1127.
Hirayama, A.V., Gauthier, J., Hay, K.A., Voutsinas, J.M., Wu, Q., Gooley, T., et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133:17 (2019), 1876–1887.
Rossi, J., Paczkowski, P., Shen, Y.W., Morse, K., Flynn, B., Kaiser, A., et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132:8 (2018), 804–814.
Kochenderfer, J.N., Somerville, R.P.T., Lu, T., Shi, V., Bot, A., Rossi, J., et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T Cells are associated with high serum interleukin-15 Levels. J Clin Oncol 35:16 (2017), 1803–1813.
Park, J.H., Riviere, I., Gonen, M., Wang, X., Senechal, B., Curran, K.J., et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:5 (2018), 449–459.
Gardner, R.A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:25 (2017), 3322–3331.
Schultz, L., Chimeric antigen receptor T Cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes. Front Immunol, 11, 2020, 1985.
Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:6 (2015), 581–590.
Calderon, H., Mamonkin, M., Guedan, S., Analysis of CAR-mediated tonic signaling. Methods Mol Biol 2086 (2020), 223–236.
Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey AD Jr., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:2 (2016), 380–390.
Salter, A.I., Ivey, R.G., Kennedy, J.J., Voillet, V., Rajan, A., Alderman, E.J., et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal, 11(544), 2018.
Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, L.J., Miklos, D.B., Jacobson, C.A., et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 377:26 (2017), 2531–2544.
Mueller, K.T., Maude, S.L., Porter, D.L., Frey, N., Wood, P., Han, X., et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130:21 (2017), 2317–2325.
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M.C.J., Strati, P., Chasen, B., et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26:12 (2020), 1878–1887.
Yakoub-Agha, I., Moreau, A.S., Ahmad, I., Borel, C., Hadhoum, N., Masouridi-Levrat, S., et al. Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC). Bull Cancer 106:1S (2019), S102–S109.
Hay, K.A., Hanafi, L.A., Li, D., Gust, J., Liles, W.C., Wurfel, M.M., et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:21 (2017), 2295–2306.
Brudno, J.N., Kochenderfer, J.N., Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev 34 (2019), 45–55.
Wang, Z., Han, W., Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res, 6, 2018, 4.
Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:6 (2016), 664–679.
Cornillon, J., Hadhoum, N., Roth-Guepin, G., Quessar, A., Platon, L., Ouachee-Chardin, M., et al. Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC). Bull Cancer, 2019.
Santomasso, B.D., Park, J.H., Salloum, D., Riviere, I., Flynn, J., Mead, E., et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:8 (2018), 958–971.
Gust, J., Hay, K.A., Hanafi, L.A., Li, D., Myerson, D., Gonzalez-Cuyar, L.F., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:12 (2017), 1404–1419.
Parker, K.R., Migliorini, D., Perkey, E., Yost, K.E., Bhaduri, A., Bagga, P., et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell, 183(1), 2020 [126-142 e117].
Logue, J.M., Zucchetti, E., Bachmeier, C.A., Krivenko, G.S., Larson, V., Ninh, D., et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica, 2020.
Hill, J.A., Li, D., Hay, K.A., Green, M.L., Cherian, S., Chen, X., et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131:1 (2018), 121–130.
Park, J.H., Romero, F.A., Taur, Y., Sadelain, M., Brentjens, R.J., Hohl, T.M., et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T Cells. Clin Infect Dis 67:4 (2018), 533–540.
Hill, J.A., Seo, S.K., How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136:8 (2020), 925–935.
Jena, B., Maiti, S., Huls, H., Singh, H., Lee, D.A., Champlin, R.E., et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One, 8(3), 2013, e57838.
Chen, P.H., Lipschitz, M., Weirather, J.L., Jacobson, C., Armand, P., Wright, K., et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight, 5(12), 2020.
Hu, Y., Huang, J., The chimeric antigen receptor detection toolkit. Front Immunol, 11, 2020, 1770.
Vogelstein, B., Kinzler, K.W., Digital PCR. Proc Natl Acad Sci U S A 96:16 (1999), 9236–9241.
Mika, T., Maghnouj, A., Klein-Scory, S., Ladigan-Badura, S., Baraniskin, A., Thomson, J., et al. Digital-droplet PCR for quantification of CD19-directed CAR T-Cells. Front Mol Biosci, 7, 2020, 84.
Wang, H., Du, X., Chen, W.H., Lou, J., Xiao, H.L., Pan, Y.M., et al. Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T Cells in peripheral blood. Transplant Proc 50:1 (2018), 104–109.
Fehse, B., Badbaran, A., Berger, C., Sonntag, T., Riecken, K., Geffken, M., et al. Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel. Mol Ther Methods Clin Dev 16 (2020), 172–178.
Lin, H.T., Okumura, T., Yatsuda, Y., Ito, S., Nakauchi, H., Otsu, M., Application of droplet digital PCR for estimating vector copy number states in stem cell gene therapy. Hum Gene Ther Methods 27:5 (2016), 197–208.
Flower, L., Ahuja, R.H., Humphries, S.E., Mohamed-Ali, V., Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 12:11 (2000), 1712–1716.
Aldo, P., Marusov, G., Svancara, D., David, J., Mor, G., Simple plex: a novel multi-analyte, automated microfluidic immunoassay platform for the detection of human and mouse cytokines and chemokines. Am J Reprod Immunol 75:6 (2016), 678–693.
Tipton, R., Yakoub-Agha I:, How we harmonize HSCT clinical practices among the SFGM-TC centers. Bull Cancer 103:11S (2016), S193–S197.
Yakoub-Agha, I., Ferrand, C., Chalandon, Y., Ballot, C., Castilla Llorente, C., Deschamps, M., et al. Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bull Cancer 104:12S (2017), S43–S58.
